New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications.

Article Details

Citation
Copy to clipboard

Weiss MJ

New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications.

Oncologist. 2003;8 Suppl 3:18-29.

PubMed ID
14671225 [ View in PubMed
]
Abstract

Recombinant human erythropoietin (epoetin alfa) has proven beneficial for the treatment of various anemias. The mechanism of action of endogenous erythropoietin and the therapeutic use of epoetin alfa to stimulate red blood cell production and improve the quality of life in cancer patients are reviewed here. Epoetin alfa may also attenuate the cognitive dysfunction associated with cancer therapy. Interestingly, functional endogenous erythropoietin receptor signaling pathways have been demonstrated in numerous nonerythropoietic tissues. Of particular importance, epoetin alfa confers neurotrophic and neuroprotective effects in cultured neurons and in several animal models for neurologic disease. In one clinical trial, epoetin alfa appeared to limit functional and histologic damage in patients with stroke. Therefore, in cancer patients receiving chemotherapy, the beneficial effects of epoetin alfa could be mediated not only through enhanced erythrocyte production but also via direct effects on the nervous system. Further investigation into the nonerythropoietic effects of epoetin alfa could broaden its clinical utility for patients with cancer and also provide new therapies for various neurologic disorders.

DrugBank Data that Cites this Article

Drugs